End-of-day quote
Kuwait S.E.
23:00:00 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.0521
KWD
|
+9.68%
|
|
+9.00%
|
-7.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
139.5
|
129.5
|
115.1
|
122.4
|
76.78
|
57.92
|
Enterprise Value (EV)
1 |
126.1
|
112.9
|
118.9
|
111.3
|
67.12
|
50.86
|
P/E ratio
|
6.97
x
|
6.57
x
|
-5.48
x
|
79.9
x
|
-17.5
x
|
-5.89
x
|
Yield
|
5.97%
|
-
|
-
|
7.63%
|
-
|
-
|
Capitalization / Revenue
|
2.8
x
|
2.02
x
|
3.8
x
|
1.51
x
|
1.06
x
|
0.91
x
|
EV / Revenue
|
2.53
x
|
1.76
x
|
3.93
x
|
1.37
x
|
0.93
x
|
0.8
x
|
EV / EBITDA
|
4.43
x
|
3.47
x
|
47.7
x
|
13.6
x
|
44.1
x
|
-492
x
|
EV / FCF
|
114
x
|
24.1
x
|
-9.79
x
|
4.34
x
|
-7.84
x
|
4.73
x
|
FCF Yield
|
0.87%
|
4.15%
|
-10.2%
|
23%
|
-12.8%
|
21.1%
|
Price to Book
|
0.67
x
|
0.6
x
|
0.63
x
|
0.65
x
|
0.46
x
|
0.38
x
|
Nbr of stocks (in thousands)
|
1,041,146
|
1,027,487
|
1,027,487
|
1,037,402
|
1,025,158
|
1,025,158
|
Reference price
2 |
0.1340
|
0.1260
|
0.1120
|
0.1180
|
0.0749
|
0.0565
|
Announcement Date
|
31/01/19
|
23/01/20
|
22/03/21
|
03/02/22
|
31/01/23
|
31/01/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
49.86
|
64.21
|
30.27
|
81.23
|
72.54
|
63.85
|
EBITDA
1 |
28.49
|
32.57
|
2.493
|
8.207
|
1.522
|
-0.1033
|
EBIT
1 |
26.29
|
28.43
|
-2.8
|
6.456
|
0.1125
|
-1.693
|
Operating Margin
|
52.72%
|
44.27%
|
-9.25%
|
7.95%
|
0.16%
|
-2.65%
|
Earnings before Tax (EBT)
1 |
23.37
|
22.39
|
-25.95
|
0.096
|
-2.715
|
-9.668
|
Net income
1 |
20.02
|
19.72
|
-21
|
1.532
|
-4.401
|
-9.836
|
Net margin
|
40.16%
|
30.71%
|
-69.37%
|
1.89%
|
-6.07%
|
-15.41%
|
EPS
2 |
0.0192
|
0.0192
|
-0.0204
|
0.001476
|
-0.004286
|
-0.009594
|
Free Cash Flow
1 |
1.102
|
4.692
|
-12.15
|
25.63
|
-8.56
|
10.75
|
FCF margin
|
2.21%
|
7.31%
|
-40.13%
|
31.55%
|
-11.8%
|
16.83%
|
FCF Conversion (EBITDA)
|
3.87%
|
14.41%
|
-
|
312.25%
|
-
|
-
|
FCF Conversion (Net income)
|
5.5%
|
23.8%
|
-
|
1,672.84%
|
-
|
-
|
Dividend per Share
2 |
0.008000
|
-
|
-
|
0.009000
|
-
|
-
|
Announcement Date
|
31/01/19
|
23/01/20
|
22/03/21
|
03/02/22
|
31/01/23
|
31/01/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
3.82
|
-
|
-
|
-
|
Net Cash position
1 |
13.4
|
16.5
|
-
|
11.1
|
9.66
|
7.06
|
Leverage (Debt/EBITDA)
|
-
|
-
|
1.531
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
1.1
|
4.69
|
-12.1
|
25.6
|
-8.56
|
10.7
|
ROE (net income / shareholders' equity)
|
9.57%
|
9.04%
|
-11.1%
|
0.04%
|
-1.36%
|
-5.38%
|
ROA (Net income/ Total Assets)
|
4.87%
|
4.75%
|
-0.48%
|
1.26%
|
0.03%
|
-0.43%
|
Assets
1 |
411.4
|
414.8
|
4,381
|
121.6
|
-17,057
|
2,279
|
Book Value Per Share
2 |
0.2000
|
0.2100
|
0.1800
|
0.1800
|
0.1600
|
0.1500
|
Cash Flow per Share
2 |
0.0500
|
0.0300
|
0.0200
|
0.0200
|
0.0100
|
0.0100
|
Capex
1 |
5.12
|
5.98
|
9.82
|
5.38
|
1.83
|
-
|
Capex / Sales
|
10.26%
|
9.31%
|
32.45%
|
6.62%
|
2.53%
|
-
|
Announcement Date
|
31/01/19
|
23/01/20
|
22/03/21
|
03/02/22
|
31/01/23
|
31/01/24
|
|
1st Jan change
|
Capi.
|
---|
| -7.79% | 158M | | +22.69% | 43.81B | | +25.56% | 23.01B | | +18.00% | 15.27B | | +8.91% | 13.68B | | +42.72% | 11.96B | | -7.49% | 6.98B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.26% | 5.59B |
Generic Pharmaceuticals
|